Reneo Pharmaceuticals, Inc. — Form 10-Q Summary
Reporting period: Three months ended March 31, 2021; filed May 20, 2021. The supplied filing identifies the registrant as Reneo Pharmaceuticals, Inc., not OnKure Therapeutics, Inc.; investors should verify the company and filing association.
Business Context and Reporting Period
Reneo is a clinical-stage pharmaceutical company developing REN001, an oral PPARδ agonist for rare genetic mitochondrial diseases. Target indications include primary mitochondrial myopathies, long-chain fatty acid oxidation disorders and McArdle disease. The company had no approved products and no product revenue.
- STRIDE, a global randomized Phase 2b trial in primary mitochondrial myopathies, was expected to begin enrollment in mid-2021, with results anticipated in 2023.
- Phase 1b studies in long-chain fatty acid oxidation disorders and McArdle disease were enrolling, with results anticipated in the first half of 2022.
- The FORWARD observational study in long-chain fatty acid oxidation disorders was expected to report results in the second half of 2022.
Financial Performance and Liquidity
| Metric | Q1 2021 | Q1 2020 | Change |
|---|---|---|---|
| Revenue | $0 | $0 | No product revenue |
| Research and development expense | $5.472 million | $3.578 million | +$1.894 million |
| General and administrative expense | $1.742 million | $0.924 million | +$0.818 million |
| Total operating expenses | $7.214 million | $4.502 million | +$2.712 million |
| Net loss | $7.212 million | $4.431 million | +$2.781 million loss |
| Net loss per share | $3.48 | $2.20 | Greater loss per share |
| Net cash used in operating activities | $8.589 million | $4.447 million | +$4.142 million use |
- Cash and cash equivalents were $91.221 million at March 31, 2021, compared with $53.613 million at December 31, 2020.
- Accumulated deficit was $52.170 million; total liabilities were $3.962 million. The filing reports no debt financing or material debt balances.
- Financing cash flow was $46.222 million, primarily from $47.258 million of net Series B preferred-stock proceeds, partially offset by $1.223 million of IPO-related costs.
- Stock-based compensation was $471,000, up from $92,000 in the prior-year quarter.
- Operating margins and profitability were not meaningful because the company had no revenue and incurred operating losses.
Material Changes Versus the Prior Comparable Period
- R&D expense increased 53%, primarily because of higher clinical trial costs associated with the STRIDE and FORWARD studies and increased personnel costs.
- G&A expense increased 89%, driven mainly by higher employee, personnel and professional-service costs.
- Net cash used in operations nearly doubled as clinical development activities expanded.
- In March 2021, the company completed the second Series B preferred-stock closing, issuing 23,440,514 shares for approximately $47.4 million of gross proceeds.
- After quarter-end, on April 13, 2021, the company completed its IPO of 6,250,000 common shares at $15.00 per share, generating approximately $84.8 million of net proceeds. All 71,183,500 outstanding preferred shares automatically converted into 15,907,629 common shares.
- On April 5, 2021, the company effected a 1-for-4.4748 reverse stock split, reflected retroactively in the financial statements.
Guidance, Outlook, Risks and Unusual Items
- Management expected continued and increasing net losses as clinical trials, manufacturing development, regulatory activities and public-company costs expanded.
- Management stated that cash at March 31, 2021 plus IPO proceeds was expected to fund operations for at least 24 months under its current plan; the liquidity note also states funding for at least one year from issuance of the report.
- COVID-19 caused the early closure of the Phase 1b primary mitochondrial myopathy trial, temporarily paused enrollment in certain other trials and delayed trial-site monitoring and study-report finalization.
- REN001 was the company’s only product candidate, creating substantial concentration risk. Regulatory approval, clinical efficacy, patient enrollment, safety, manufacturing, reimbursement and commercialization remained uncertain.
- The company relied on third-party contract research organizations and manufacturers, including single-source suppliers for REN001 clinical materials.
- The vTv Therapeutics license requires potential development and regulatory milestone payments of up to $64.5 million, sales-based milestones of up to $30.0 million and tiered royalties at mid-single-digit to low-teen percentage rates.
- A $7.5 million performance bonus for the chief executive officer became payable upon achievement of specified market-value or change-in-control conditions; the IPO satisfied the performance condition, and compensation expense was expected to begin in April 2021.
- The company reported no material legal proceedings and no off-balance-sheet arrangements. Disclosure controls were concluded to be effective as of March 31, 2021.
Most Important Facts for Investors to Verify
- Verify that this filing belongs to Reneo Pharmaceuticals rather than the requested OnKure Therapeutics entity.
- Reconcile the post-quarter-end IPO proceeds, share conversion, reverse stock split and resulting common-share count with subsequent filings.
- Assess whether the stated 24-month cash runway remains valid as clinical-trial spending and public-company costs increase.
- Track STRIDE enrollment, trial execution and the anticipated 2022–2023 clinical readouts.
- Review REN001 safety data, including the reported incipient cataract in one McArdle disease patient, and any resulting regulatory requirements.
- Evaluate the economics, remaining obligations and patent coverage under the vTv Therapeutics license.
- Monitor additional financing needs, potential dilution and the effect of preferred-stock conversion and equity compensation.